Intellia Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Intellia Therapeutics company profile

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts.

Business identity

Contact email
[email protected]
Phone number
(857) 285-6200
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$50,000+
Founded
2014-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$1.5B
Last funding
Post IPO Equity / $300M / 2022-11-30
Last equity funding
Post IPO Equity / $300M
Investors
9
Lead investors
3
Founders
7
Articles
581
Exited on
2016-05-06

Founders and investors

Founders

Andy MayDerrick RossiErik SontheimerJennifer DoudnaLuciano MarraffiniNessan BerminghamRodolphe Barrangou

Lead investors

Atlas VentureNovartisOrbiMed

Investors

Atlas VentureFidelityForesite CapitalNovartisOrbiMed